Prognostic effect of consolidation treatment per ELN risk group and MRD status. In favorable- and intermediate-risk patients, non-alloSCT treatment does not negatively affect survival compared to alloSCT in MRD-negative patients. In adverse risk patients, the alloSCT is beneficial independent of MRD. Combined data (means and standard error of the mean) calculated from Zhang et al,¹⁹  Venditti et al (intermediate risk-patients),²⁰  and Tettero et al.²²